Özsaygili C, et al. - Researchers conducted this retrospective cohort study to examine the impact of posterior vitreous detachment (PVD) on aflibercept response in treatment-naïve diabetic macular oedema (DME). One hundred and fifty eyes of 150 treatment-naïve patients with DME have been recruited. Study participants were divided into three groups according to their PVD status: group 1 (no PVD during injections), group 2 (PVD during injections), and group 3 (PVD already present initially). The mean reduction of CRT in groups 1, 2, and 3 were −199.6±106.9, −224.9±124.1, and −210.7±126.3, respectively, after three consecutive injections. No significant link was found between the presence or development of PVD and the mean decrease of CRT and the improvement of BCVA. It was noted that the effectiveness of treatment with aflibercept in DME patients did not depend on the PVD status.